176 related articles for article (PubMed ID: 17653858)
1. Issues and controversies in the treatment of HER2 positive metastatic breast cancer.
Amar S; Moreno-Aspitia A; Perez EA
Breast Cancer Res Treat; 2008 May; 109(1):1-7. PubMed ID: 17653858
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.
Del Mastro L; Lambertini M; Bighin C; Levaggi A; D'Alonzo A; Giraudi S; Pronzato P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1391-405. PubMed ID: 23072512
[TBL] [Abstract][Full Text] [Related]
7. An overview of HER-targeted therapy with lapatinib in breast cancer.
McArthur H
Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Guarneri V
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1549-57. PubMed ID: 19895239
[TBL] [Abstract][Full Text] [Related]
10. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
11. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
12. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic breast cancer: looking towards the future.
Amar S; Roy V; Perez EA
Breast Cancer Res Treat; 2009 Apr; 114(3):413-22. PubMed ID: 18465221
[TBL] [Abstract][Full Text] [Related]
14. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
17. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
19. Overcoming treatment challenges in advanced breast cancer.
Harkins B; Geyer CE
Semin Oncol Nurs; 2007 Nov; 23(4 Suppl 2):S10-6. PubMed ID: 18054677
[TBL] [Abstract][Full Text] [Related]
20. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
